SCHEMBL29367281

SCHEMBL29367281

COc1ccc(F)cc1CC(=O)Nc1nccs1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.67
LMNA P02545 2/20 0.67
MAPK1 P28482 2/20 0.67
RAB9A P51151 5/20 0.57
NPC1 O15118 3/20 0.57
ALDH1A1 P00352 2/20 0.57
POLB P06746 1/20 0.57
ADRB2 P07550 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
TP53 P04637 1/20 0.56
HPGD P15428 1/20 0.56
ALOX15 P16050 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
CSNK1D P48730 1/20 0.54
PKM P14618 1/20 0.53
KCNMA1 Q12791 1/20 0.52
KDM4E B2RXH2 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
BRD4 O60885 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28350045 1.00 SMN1; SMN2 (0.67) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL28353263 0.87 LMNA (0.66) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL30765198 0.87 LMNA (0.66) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL28350195 0.86 RAB9A (0.67) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL20577404 0.84 SMN1; SMN2 (0.56) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL28354689 0.79 SMN1; SMN2 (0.46) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL30765132 0.78 LMNA (0.63) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL1340856 0.77 RAB9A (0.58) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL29855806 0.77 NPC1 (0.62) SMN1; SMN2RAB9ANPC1ALDH1A1POLB
SCHEMBL28350334 0.77 NPC1 (0.62) SMN1; SMN2RAB9ANPC1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110753691-B Compounds for therapeutic and/or prophylactic treatment of cancer 豪夫迈·罗氏有限公司 2024-02-02 CN disclosed
EP-3986565-B1 NEW EGFR INHIBITORS HOFFMANN LA ROCHE (CH) 2023-08-30 EP disclosed
EP-3630754-B1 ISOINDOLINE-ACETYLENE COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2022-07-27 EP disclosed
CN-113993589-A Novel EGFR inhibitors 豪夫迈·罗氏有限公司 2022-01-28 CN disclosed